Paradigm faces restructuring risk after trial fails futility threshold

Phase 3 trial fails continuation threshold

Paradigm Biopharmaceuticals Ltd (Administrators Appointed) (ASX:PAR) has reported a decisive setback for its lead clinical program: the interim analysis of the PARA_OA_012 Phase 3 knee osteoarthritis trial met the study’s pre-specified futility criterion. The independent Data Safety Monitoring Board found interim efficacy below the threshold required for the trial to continue, after about half of participants reached the Day 112 primary endpoint.

The trial had treated 538 participants with a six-week course of twice-weekly injectable pentosan polysulfate, or iPPS, compared with placebo. Paradigm said the study also faced operational challenges and significant missing data, prompting a review of pain, physical function, safety, treatment exposure, data completeness and regional differences. The company’s overall trial result remains the central problem, even as further analysis continues.

Regional data offers a limited counterpoint

Since quarter end, a Rest of World analysis has identified encouraging pain and function findings, according to the report. That analysis is being independently assessed, but it does not change the reported futility outcome or revive the trial’s planned path. Earlier coverage described a regional iPPS benefit outside the United States, while also noting that the overall Phase 3 result remained unchanged: regional iPPS analysis.

The administrators caution that they have not independently verified the clinical data or the company’s analysis. Any decision about further clinical work therefore remains subject to the administration process, available funding and the assessment of the underlying dataset.

Cash position leaves little room for delay

Paradigm ended September with A$4.33 million in cash and cash equivalents, down from A$15.37 million at the end of June. Net cash used in operating activities was A$13.45 million, including A$17.48 million in research and development payments tied mainly to trial treatment, site operations, monitoring, investigational product supply and data management.

The Appendix 4C calculates only 0.3 quarters of funding based on the quarter’s operating cash outflow and available cash. That measure is not a forecast of spending under administration, however: the report says the appointment of administrators changed how future expenditure and commitments would be assessed. Paradigm also expects an A$8.4 million FY26 R&D tax refund by the end of calendar 2026, but the amount and timing remain subject to assessment and the money has not been received.

Administration extends while restructuring options remain open

FTI Consulting’s Hayden White and Chris Pattinson took control of Paradigm’s business, property and affairs on 29 September, with officers’ powers suspended and the company’s securities remaining suspended. The board intends to work with stakeholders on a proposed deed of company arrangement aimed at restructuring liabilities, preserving intellectual property and data, and assessing future business options, but the report stresses there is no certainty a DOCA will be approved or implemented.

The Supreme Court of Western Australia has now granted the administrators an extension of up to three months to the convening period, a development covered in the court-approved administration extension. That gives the process more time, not a resolution: the eventual outcome still depends on proposals, creditor considerations, funding and the administrators’ assessment.

Debt movements sharpen the capital question

Paradigm drew US$3 million, described as approximately A$4.3 million, under its Obsidian convertible note facility in July. It also drew US$2 million in September, equivalent to A$2.79 million, but agreed to return that tranche after the interim analysis outcome; the related notes were cancelled without a premium, fee or other additional payment.

The company’s securities will remain suspended unless ASX is satisfied that Paradigm complies with the Listing Rules and that reinstatement is appropriate. For shareholders, the unresolved issue is no longer simply whether the clinical dataset contains a useful regional signal. It is whether that signal, the company’s intellectual property and the proposed funding or restructuring pathway can support a viable future under administration.